COMMITTEE OPINION

Number 540 • November 2012

Committee on Gynecologic Practice

This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.

s of enous hro boe bo s A ong sers of Drosp renone Conta n ng Ora Contracept ve P s

ABSTRACT: Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones, and some data have suggested that use of drospirenone-containing pills has a higher risk of venous thromboembolism, this risk is still very low and is much lower than the risk of venous thromboembolism during pregnancy and the immediate postpartum period. When prescribing any oral contraceptive, clinicians should consider a woman's risk factors for venous thromboembolism and refer to the **U.S. Medical Eligibility Criteria for Contraceptive Use** issued by the Centers for Disease Control and Prevention. Patient education materials, including product labeling, should place information regarding oral contraceptive use and venous thromboembolism risks in context by also providing information about overall venous thromboembolism risks during pregnancy and the postpartum period. Decisions regarding choice of oral contraceptive should be left to clinicians and their patients, taking into account the possible minimally increased risk of venous thromboembolism, patient preference, and available alternatives.

n / ora ontra pt v s. Cs t, at onta n / ro. , av su : st / a, .; rrs o v noust, ro o asso at / w t, t, us o Cs t, at onta n / rosp r . non o par / w t, Cs t, at onta n ot, r pro 'st ns. su, as vonor str , , wo ar stu s, on ar Dut, as - ontro stu/, an/ on o, ort stu/, ro D n ar \ a so r port / n r as / r s s o v nous t, ro o os wt, us o rosprnon, ontann Cs o par / w t, vonor str , onta n n · Cs , . . . How v r. t, s stu/ s, a/s v ra t o oo a tat ons., su, as pot nt a s ass, at on o v nous os an t, urat on o us o t na/ quat ontro o on oun/ n 'var a s, an/ pot n ta nor aton an / t ton as s. \ D sp t t s to ons / r an tat ons, t s oo a paus $n \ r \ as \ / \ r \ s \ o_{\prime} \ o \ p \ at \ ons \ _{\prime} \ ro$ v nous t ro os w t, t, us o / rosp r non , onta n n $^{\circ}$ Cs as o par / wt ot r pro st n onta n n · Cs a. nvo v / w t, ostas s., a/n 'to a ras noa ua t, ror, t ant nrao. ort o / prop rt s o / rosp r non ou / n turn a/ to

n r as / rs o v nous t ro o o s w t t us o / rosp r non onta n n · Cs, \

Atrrv wn t ata nţ s asw asoţ rstu/, s,t, Foo an Dru A n strat on FDA ssu a Drug Safety Communication n w, $t on u \neq t$, at us o rosp r non onta n n · Cs a. wta, ; rrs o oo otstan ot rpro stn onta n n · Cs B aus t stu/ s / / not prov / ons st nt st at s o t, o parat v r s o oo ots tw n / rosp r non, onta n n · Cs an / ot, r pro st n onta n n · Cs an/ aus t stu s a to a ount or portant pat nt , ara t r st s, su , as s o n status an/ o/, ass n/ ,t, at a, n/ u n . a, tt, rs o, oo/ prsr n an/ FDA was una to on u ausa t.

wonst/as-ontrostustatus/int/
tatsan/int/Kn/ona/ataassoun/t,
rsononata/opat/vnoustrooos to
two to tr ts, ; ra on nw urr nt us rso
vonor str, ontann Cs, in Inor at onr ar,
n C us was as rtan/roap, ar a /ataas

r or / / ro / ru ' a s n on stu/. , \ an / ro a r s ar , / ata as n t, ot, r stu/. , \ A / nt / ro pat nts w t, v nous t, ro o o s , a/ to , av r v / on; t r ant oa u at on t, rap. In on

• Decisions regarding the choice of OC should be left to n ans and t r pat nts, tanninto a ount t, lo own ha tors

t, poss na.nras/rsovnous
t, rooosnnwusrso/rosprnon
ontann Csopar/wt, usrsoon/
Cs, / //// wo an, arsopar/wt,
- ///// wo an, ars, F

- Women should have a wide range of contraceptive opt ons. n u n rosp r non, onta n n Cs
- If a patient is using a drospirenone-containing OC an s to rat n · t, r · · n, t, r s no n / to / s ont nu t, at C
- When prescribing any OC, dinicians should consider a woman's radius a torsion vinous to romo ones and radius roto to the U.S. Medical Eligibility Criteria for Contraceptive Use

•soffatiient education materials t I reouca

Committee Opinion No. 540

I

//

3